Consolidation therapies applied in the donor and no-donor groups
| Type of therapy . | Group of patients . | |
|---|---|---|
| Donor (n = 96) . | No donor (n = 161) . | |
| Allogeneic SCT | ||
| HLA-identical sibling | 91 (95%) | — |
| Unrelated donor | — | 29 (18%) |
| Mismatched family donor | — | 2 (1%) |
| Autologous SCT | 3 (3%) | 123 (76%) |
| Maintenance only | 1 (1%) | 3 (2%) |
| No treatment | 1 (1%) | 4 (2%) |
| Type of therapy . | Group of patients . | |
|---|---|---|
| Donor (n = 96) . | No donor (n = 161) . | |
| Allogeneic SCT | ||
| HLA-identical sibling | 91 (95%) | — |
| Unrelated donor | — | 29 (18%) |
| Mismatched family donor | — | 2 (1%) |
| Autologous SCT | 3 (3%) | 123 (76%) |
| Maintenance only | 1 (1%) | 3 (2%) |
| No treatment | 1 (1%) | 4 (2%) |
SCT indicates stem cell transplantation; and HLA, human leukocyte antigen.